{"url_path":"/sec/nbix/8-k/2026-05-18/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-18","source_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","accession_number":"0001193125-26-228013","cik":"0000914475","ticker":"NBIX","issuer_name":"NEUROCRINE BIOSCIENCES INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/914475/0001193125-26-228013-index.html","primary_entity_key":"0000914475","primary_entity_name":"NEUROCRINE BIOSCIENCES INC"},"word_count":546,"has_tables":true,"body_markdown":"8-K\n\nNEUROCRINE BIOSCIENCES INC false 0000914475 0000914475 2026-05-14 2026-05-14\n\n \n\n \n\nUNITED STATES\n\nSECURITIES AND EXCHANGE COMMISSION\n\nWASHINGTON, D.C. 20549\n\n \n\n \n\nFORM 8-K\n\n \n\n \n\nCURRENT REPORT\n\nPursuant to Section 13 or 15(d)\n\nof the Securities Exchange Act of 1934\n\nDate of Report (Date of earliest event reported): May 14, 2026\n\n \n\n \n\n \n\nNEUROCRINE BIOSCIENCES, INC.\n\n(Exact name of Registrant as Specified in Its Charter)\n\n \n\n \n\n \n\nDelaware\n \n0-22705\n \n33-0525145\n\n(State or Other Jurisdiction\n\nof Incorporation)\n\n \n\n(Commission\n\nFile Number)\n\n \n\n(IRS Employer\n\nIdentification No.)\n\n \n\n6027 Edgewood Bend Court\n \n\nSan Diego, California\n \n92130\n\n(Address of Principal Executive Offices)\n \n(Zip Code)\n\n(858) 617-7600\n\n(Registrant’s telephone number, including area code)\n\nN/A\n\n(Former name or former address, if changed since last report)\n\n \n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n \n☐\n\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n \n☐\n\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n☐\n\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n \n☐\n\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\n \n\nTrading\nSymbol\n\n \n\nName of each exchange\non which registered\n\nCommon Stock, $0.001 par value\n \nNBIX\n \nNasdaq Global Select Market\n\nIndicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).\n\nEmerging growth company ☐\n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n \n\nIntroductory Note\n\nAs previously disclosed in the Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) by Neurocrine Biosciences, Inc., a Delaware corporation (the “Company”), on April 6, 2026, the Company entered into an Agreement and Plan of Merger, dated as of April 5, 2026 (the “Merger Agreement”), with Sigma Merger Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of the Company (“Purchaser”), and Soleno Therapeutics, Inc., a Delaware corporation (“Soleno”). Pursuant to the Merger Agreement, on April 20, 2026, the Company, through Purchaser, commenced a tender offer to purchase all the outstanding shares of Soleno’s common stock, par value $0.001 per share (the “Soleno Shares”), at a price of $53.00 per Soleno Share (the “Offer Price”), in cash, without interest and subject to any required withholding taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated April 20, 2026 (together with any amendments or supplements thereto, the “Offer to Purchase”) and in the related Letter of Transmittal (together with any amendments or supplements thereto, the “Letter of Transmittal”; the Offer to Purchase and the Letter of Transmittal, collectively, the “Offer”). The Offer to Purchase and the Letter of Transmittal were filed as Exhibits (a)(1)(A) and (a)(1)(B), respectively, to the Tender Offer Statement on Schedule TO originally filed with the SEC by Purchaser and the Company on April 20, 2026."}